LWMG
XBI icon

Levy Wealth Management Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Levy Wealth Management Group’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,478
Closed -$200K – 70
2021
Q2 		$200K Buy
+1,478
New +$194K 0.12% 68

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Levy Wealth Management Group's XBI Position: Q3 2021 in Review

Levy Wealth Management Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 1,478 shares — an estimated $200K sold.

Levy Wealth Management Group first reported a position in XBI in Q2 2021 and held it in 1 quarter. The position peaked at $200K in Q2 2021. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

  • Levy Wealth Management Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
  • Levy Wealth Management Group sold 1,478 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $200K.
  • Levy Wealth Management Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 1 quarter.
  • Levy Wealth Management Group's State Street SPDR S&P Biotech ETF position peaked at $200K in Q2 2021.
  • 635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Levy Wealth Management Group's 13F filing for Q3 2021, filed 26 Oct 2021.